{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:42:38Z","timestamp":1793302958949,"version":"4.5.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"\n Importance<\/jats:title>\n Interleukin 6 (IL-6), a keystone inflammatory cytokine, is a credible mechanistic candidate for causing depression. However, randomized clinical trials testing its treatment potential remain scarce.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To identify likely treatment-sensitive outcomes and effect size for systemic IL-6 inhibition in patients with difficult-to-treat depression.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This 4-week, proof-of-concept, double-blind, parallel-arm, placebo-controlled randomized clinical trial recruited adults with moderate-to-severe\n International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)<\/jats:italic>\n depression, poor antidepressant response, low-grade systemic inflammation (high-sensitivity C-reactive protein [hs-CRP] level \u22650.3 mg\/dL on 2 tests), and depression somatic symptoms (Beck Depression Inventory II somatic symptoms score \u22657) from primary and secondary care and self-referral from 2018 to 2022. Participants were randomized into minimization balanced groups on depression severity and sex. Assessments were conducted at baseline and 7, 14, and 28 days after infusion. Data were analyzed from 2023 to 2025.\n <\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Single intravenous infusion of IL-6R antagonist tocilizumab (8 mg\/kg, maximum 800 mg\/patient) or normal saline.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was depression somatic symptoms at 14 days after infusion. The secondary outcome was total depression severity. Exploratory outcomes included fatigue, anxiety, anhedonia, quality of life, and cognition. Outcomes were assessed using validated scales and interpreted against clinically meaningful thresholds.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 30 participants (mean [SD] age, 41.1 [12.3] years; 24 [80.0%] female) were randomized, including 14 in the tocilizumab group and 16 in the placebo group. Of these, 29 participants received the assigned infusion and completed follow-up. As expected for a small proof-of-concept study, no results reached statistical significance, including little improvement in depression somatic symptoms at day 14 (adjusted mean difference: \u22120.12; 95% CI, \u22122.51 to 2.28). However, a pattern of greater stepwise improvement over time was observed with tocilizumab in somatic symptoms, depression severity, fatigue, psychological symptoms, state anxiety, and quality of life, with the largest effects observed at the final follow-up (day 28). Tocilizumab may also improve more individual depressive symptoms. Treatment effects were within ranges considered clinically meaningful for depression severity, fatigue, anxiety, and quality of life. At the final follow-up, remission (7 participants [53.9%] vs 5 participants [31.3%]; number needed to treat [NNT]\u2009=\u20095) and response (6 participants [46.2%] vs 3 participants [18.8%]; NNT\u2009=\u20094) rates favored tocilizumab compared with placebo. Baseline hs-CRP level, but not IL-6 level, tracked depression improvement, suggesting hs-CRP may better predict immunotherapy response in depression than drug-specific biomarkers. Tocilizumab was well tolerated, with no serious adverse events or withdrawals.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n These findings highlight treatment-sensitive outcomes, effect sizes, and patient selection methods for testing systemic IL-6 inhibition in patients with difficult-to-treat depression, and call for a large-scale efficacy trial of anti\u2013IL-6 treatment in depression.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n isrctn.org Identifier:\n ISRCTN16942542<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2026.1053","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:30:25Z","timestamp":1779291025000},"page":"857","source":"Crossref","is-referenced-by-count":10,"title":["Interleukin 6 as a Treatment Target for Depression"],"prefix":"10.1001","volume":"83","author":[{"given":"\u00c9imear M.","family":"Foley","sequence":"first","affiliation":[{"name":"MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom"},{"name":"Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Turner","sequence":"additional","affiliation":[{"name":"Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta","family":"Margelyte","sequence":"additional","affiliation":[{"name":"MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom"},{"name":"Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah J.","family":"Jones","sequence":"additional","affiliation":[{"name":"MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom"},{"name":"Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom"},{"name":"NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffer","family":"Kaser","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom"},{"name":"Cambridgeshire and Peterborough NHS Trust, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glyn","family":"Lewis","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom"},{"name":"Cambridgeshire and Peterborough NHS Trust, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golam M.","family":"Khandaker","sequence":"additional","affiliation":[{"name":"MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom"},{"name":"Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom"},{"name":"NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom"},{"name":"Avon and Wiltshire Mental Health Partnership NHS Trust, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"ybr260003r1","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1017\/S0033291719001454","article-title":"Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels.","volume":"49","author":"Osimo","year":"2019","journal-title":"Psychol Med"},{"issue":"1","key":"ybr260003r2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1192\/bjp.2018.66","article-title":"Treatment-resistant depression and peripheral C-reactive protein.","volume":"214","author":"Chamberlain","year":"2019","journal-title":"Br J Psychiatry"},{"issue":"12","key":"ybr260003r3","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/mp.2016.3","article-title":"A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.","volume":"21","author":"Goldsmith","year":"2016","journal-title":"Mol Psychiatry"},{"issue":"10","key":"ybr260003r4","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/jamapsychiatry.2014.1332","article-title":"Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study.","volume":"71","author":"Khandaker","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"ybr260003r5","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41380-019-0395-3","article-title":"Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort.","volume":"25","author":"Khandaker","year":"2020","journal-title":"Mol Psychiatry"},{"issue":"5","key":"ybr260003r6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.biopsych.2009.03.015","article-title":"Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity.","volume":"66","author":"Harrison","year":"2009","journal-title":"Biol Psychiatry"},{"issue":"8","key":"ybr260003r7","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1001\/jamapsychiatry.2013.1111","article-title":"Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study.","volume":"70","author":"Benros","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"ybr260003r8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/mp.2016.167","article-title":"Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions.","volume":"23","author":"Kappelmann","year":"2018","journal-title":"Mol Psychiatry"},{"issue":"6","key":"ybr260003r9","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/s41380-019-0471-8","article-title":"Effects of immunomodulatory drugs on depressive symptoms: a mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders.","volume":"25","author":"Wittenberg","year":"2020","journal-title":"Mol Psychiatry"},{"issue":"12","key":"ybr260003r10","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1176\/appi.ajp.2021.20121776","article-title":"Association between systemic inflammation and individual symptoms of depression: a pooled analysis of 15 population-based cohort studies.","volume":"178","author":"Frank","year":"2021","journal-title":"Am J Psychiatry"},{"issue":"12","key":"ybr260003r11","doi-asserted-by":"publisher","first-page":"7393","DOI":"10.1038\/s41380-021-01188-w","article-title":"Association of inflammation with depression and anxiety: evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts.","volume":"26","author":"Milaneschi","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"9","key":"ybr260003r12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025333","article-title":"Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation.","volume":"8","author":"Khandaker","year":"2018","journal-title":"BMJ Open"},{"issue":"15","key":"ybr260003r13","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1017\/S0033291715001270","article-title":"Minimal clinically important difference on the Beck Depression Inventory\u2013II according to the patient\u2019s perspective.","volume":"45","author":"Button","year":"2015","journal-title":"Psychol Med"},{"issue":"1","key":"ybr260003r14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","article-title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.","volume":"70","author":"Raison","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"ybr260003r15","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41386-020-00948-6","article-title":"Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial.","volume":"46","author":"Nettis","year":"2021","journal-title":"Neuropsychopharmacology"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2848978\/jamapsychiatry_foley_2026_br_260003_1785440732.14672.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:00:59Z","timestamp":1785942059000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2848978"}},"subtitle":["A Proof-of-Concept Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.1053","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}